Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.

Lehman JM, Gwin ME, Massion PP
Curr Oncol Rep. 2017 19 (7): 49

PMID: 28643173 · DOI:10.1007/s11912-017-0609-2

Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.

MeSH Terms (6)

Genes, cdc Humans Immunoconjugates Immunotherapy Molecular Targeted Therapy Small Cell Lung Carcinoma

Connections (1)

This publication is referenced by other Labnodes entities:

Links